Job Summary
This position is responsible for providing leadership for China CMC activity of the portfolio both chemical drug and biological drug as a director of CMC management in China. This positionis also responsible for the on-time delivery of China clinical supplies for programs with significant technical and geographic complexity across the Daiichi Sankyo portfolio.
This individual will be to provide strategic management of high complexity teams and drive the execution of China CMC development through CMC team meeting management, leading strategic CMC development planning aligned with global CMC strategy, timeline management, stakeholder management, risk/issue management, finance and resource management, and conflict resolution as a director of CMC management.
Responsibilities
1.CMC Team management
From an overall optimum point of view and deep CMC-related knowledge, formulate clear CMC strategies (communicate well to CMC Team members). Consider the development of Plan B from the perspective of risk management. At the onset of the task, take a proactive role in solving the task.
2. Regulatory AffairsWork with RACMC to schedule regulatory affairs-related CMC tasks for clinical trial application. Collaborate with RACMC to coordinate the content and timing of consultation to authority. As one of reviews, confirm whether the requirements are appropriately reflected in the materials related to approval applications
(IND, NDA, inquiry response, etc.).
3. Coordinationand cooperation within and outside the DSCN PT division
As a representative of the CMC/CSO related tasks in DSCN PT, participate in the PJ team to accurately assess the PJ status and to provide appropriate solutions to any issues through close communication with
global PT members and China local members. Provide necessary PJ information to CMC Team members, seniors, and other stakeholders within the DSCN PT, and lead discussions on CMC issues and decisions on strategies within the DSCN PT.
4.Investigational medicinal product supply management
Planning, conflict management, and risk control of supply chain management of investigational medicinal products with no delay in China clinical trials and China MA studies.
Qualifications:
Contact: Dennis
第一三共致力于运用我们全球一流的科学技术,创造新的模态与创新药物,以实现“为提高世界各地人们的生活质量做出贡献”的目标。除了目前的肿瘤与心血管疾病药物组合外,第一三共还专注于为肿瘤患者以及其他医疗需求未得到满足的疾病患者开发新疗法。凭借自身100多年的科学专业知识和覆盖20多个国家的业务范围,第一三共及其全球16000名员工将秉承公司深厚的创新传统,努力实现我们的2030愿景,成为“为社会可持续发展做出贡献的创新型全球医疗保健公司。”
确认申请职位?修改简历